Image

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors

Trying new treatment options for resistant Hodgkin Lymphoma.

Recruiting
12 years and older
All
Phase 2

This study is looking at using two drugs, *brentuximab vedotin* and *nivolumab*, to treat a type of cancer called classic Hodgkin lymphoma. Hodgkin lymphoma is a cancer of the lymphatic system, which is part of the immune system. Some people’s cancer comes back (this is called *relapsed*) or doesn’t respond to treatment (*refractory*). Brentuximab vedotin is a special type of medicine called a monoclonal antibody that targets cancer cells and delivers a toxic agent to kill them. Nivolumab is another monoclonal antibody that helps the immune system fight cancer.

The study aims to see how well these two drugs work together in patients who have already tried them separately with other treatments. If you join this study, you will receive both drugs through an IV every 21 days, for up to 16 cycles. The doctors will check on you 30 days after the study ends, then every 3 months for 2 years, and every 6 months for 3 years.

  • Duration: Treatment cycles every 21 days, for up to 16 cycles.
  • Eligibility: Must be 12 years or older with specific previous treatments.
  • Follow-Up: Regular check-ups for up to 5 years after treatment.
Study details
    Recurrent Classic Hodgkin Lymphoma
    Refractory Classic Hodgkin Lymphoma

NCT05039073

Emory University

2 March 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.